The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

Johnson & Johnson's stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered ...

Johnson & Johnson's stock (JNJ) rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company ...

Share on Facebook Share on Twitter Today the AWESOME is in Brewer, Maine. A woman named Heather shared what she saw the other ...

Share on Facebook Share on Twitter Jason Aldean is hitting the road in 2025. He just announced his Full Throttle Tour. Jason ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

The spray, called Spravato, is now the first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard treatments does little to nothing to improve ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...